Market Research Report
Asia-pacific Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2021-2028
|Asia-pacific Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2021-2028|
Published: August 23, 2021
Content info: 151 Pages
Delivery time: 2-3 business days
KEY FINDINGS The Asia-Pacific Alzheimer's disease therapeutics and diagnostics market is estimated to register a CAGR of 5.67% during the forecast period, 2021-2028. The increasing number of age-induced dementia cases is set to propel market growth in the Asia Pacific.
China, South Korea, Japan, India, Vietnam, Indonesia, Australia & New Zealand, Thailand, and the rest of Asia-Pacific are evaluated for the Asia-Pacific Alzheimer's disease therapeutics and diagnostics market growth analysis. As per the United Nations Population Fund 2017 report, in India, the number of dementia cases is projected to reach 1.3 million in 2020 and 1.7 million by 2030. Also, the rising burden of Alzheimer's disease has led to the growing demand for new healthcare technological advancements in the treatment and early diagnosis of dementia. Moreover, the geriatric population is set to increase, which is set to drive market growth. The country is participating in massive collaborative research work for Alzheimer's. At the same time, there is a lack of industry-sponsored research for enhancing the current medications, and improving diagnostic modalities for Alzheimer's and R&D for developing new interventions. India is expected to project a moderate growth during the forecast period, despite considerable efforts at the national level for Alzheimer's.
In Australia, the number of dementia cases is expected to reach 1,076,129 by 2058, according to Dementia Australia. Further, dementia is one of the most significant healthcare challenges in New Zealand, as per Alzheimer.org data. The Australia & New Zealand Alzheimer's disease therapeutics and diagnostics market is consolidated, and the current policies and framework are estimated to fuel the market growth further.
Some of the distinguished players in the market include, Pfizer Inc, Novartis AG, GE Healthcare, Johnson & Johnson, Eli Lilly & Company, Sun Pharmaceuticals Industries Ltd, etc.